Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?

NCT03232112 on ClinicalTrials.gov · last registry update 2021-06-04

Finished 15 March 2020, after enrolling 152 people. Primary outcome, as filed: Heavy drinking days. exenatide is approved in the US, but not for alcohol use disorder and substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: Anders Fink-Jensen, MD, DMSci
Sponsor type: Other
Enrollment: 152
Started: 2017-08-07
Primary completion: 2020-03-15 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Heavy drinking days

Conditions studied

Alcohol Dependence, in Remission · Addiction, Alcohol

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.